Qulipta (atogepant)
Qulipta (atogepant) is a prescription medicine used for the prevention of episodic migraine in adults.
- Disease Indications : Migraine
- Manufacturer : AbbVie Ltd
- Usage : Oral
Medicine approved by
- Food and Drug Administration (FDA)
Details
What is Qulipta (atogepant) for?
Qulipta (atogepant) is a calcitonin gene-related peptide receptor (CGRP) antagonist indicated for the preventive treatment of episodic migraine in adults.
It is available in tablet form, each containing 10 mg, 30 mg or 60 mg atogepant.
How does Qulipta (atogepant) work?
Migraine attacks are thought to be caused by the release of a protein called CGRP. When CGRP binds to CGRP receptors, it causes pain, inflammation, and vasodilation.
The active ingredient in Qulipta, atogepant, works by blocking CGRP receptors to prevent migraine.
Where has Qulipta (atogepant) been approved?
Qulipta (atogepant) was approved for the prevention of episodic migraine by:
- The Food and Drug Administration (FDA), USA on September 28, 2021.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Qulipta (atogepant) taken?
The standard dosage is:
- 10 mg, 30 mg, or 60 mg taken orally once daily with or without food
The dose of Qulipta (atogepant) should be modified when it is used together with specific drugs or if you have kidney problems or are on dialysis.
Warning: do not take this medicine if you have severe liver disease.
Complete information about Qulipta (atogepant) dosage (modifications) and administration can be found in the official prescribing information listed in our references section.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Qulipta (atogepant)?
Common adverse reactions
The most common side effects (≥4% of patients) listed in the prescribing information include:
- Nausea
- Constipation
- Tiredness (fatigue)
Use in a specific population
It is not known if Qulipta (atogepant) will harm your unborn baby or if it passes into your breast milk. Talk to your treating doctor if you are pregnant or planning to become pregnant, or about the best way to feed your baby while taking this medicine.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.
References
- 1. Full prescribing information [FDA]: Qulipta (atogepant) [PDF] AbbVie, Sep 2021
- 2. Mechanism of action Quliptahcp.com, cited Oct 2021
- 3. FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine Abbvie press release, Sep 2021
Clinical trials
The Food and Drug Administration (FDA) approval of Qulipta (atogepant) for the prevention of episodic migraine in adults was based on data of the ADVANCE trial (NCT03777059).
ADVANCE was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that involved 910 adults. Participants were given either tablets of Qulipta 10 mg, 30 mg or 60 mg, or placebo once daily for 12 weeks.
Results
The main study endpoint was the mean monthly migraine day (MMD) reduction across 12 weeks.
All three Qulipta doses showed significant reductions in the number of migraine days and headache days over a period of 12 weeks:
- Patients receiving 10 mg had 3.7 fewer MMDs
- Patients receiving 30 mg had 3.9 fewer MMDs
- Patients receiving 60 mg had 4.2 fewer MMDs
Please refer to the summary of product characteristics below and in the resource section for comprehensive information about the safety and effectiveness of Qulipta (atogepant) for the approved indication
References
-
1. FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine Abbvie press release, Sep 2021
2. 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine ADVANCE trial, cited Oct 2021
3. Atogepant for the Preventive Treatment of Migraine Ailani J, et al., NEJM, Aug 2021
4. Full prescribing information [FDA]: Qulipta (atogepant) [PDF] AbbVie, Sep 2021
Price & Costs
Qulipta (atogepant) treatment costs
The cost for a monthly or yearly treatment of Qulipta (atogepant) depends on your prescription requirements which includes the dosage in mg and medicine type (Tablets).
The price of the medicines you see on sale is the cost set by the manufacturer. In addition, shipping costs and a Named Patient support fee will apply.
Make an enquiry and we will help you calculate the total price to buy Qulipta (atogepant) online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.
Qulipta (atogepant) price and additional costs
- The price of Qulipta (atogepant)
- Our Named Patient support fee
- Shipping costs
- Payment methods when you buy Qulipta (atogepant)
The base cost of each medicine is set by the manufacturer. Generally, our Named Patient support fee, shipping costs and any local tax (if applicable) are not included in the product price that is displayed on our website unless stated otherwise.
everyone.org provides access to Qulipta (atogepant) on the Named Patient import basis, which means that we work on behalf of the patient in cooperation with their treating doctor. Our Named Patient support fee covers sourcing, logistics and following up to make sure that the order is received safely and in perfect condition. The Named Patient support fee is tiered relative to the cost of the medicine.
The shipping prices are dependent on the type of shipping necessary for the particular medicine (regular or cold chain) and upon the destination country. The shipping fees may include the shipping from our supplier to our partner pharmacy as well as the shipping costs to deliver the medicine to the patient’s country of residence. The shipping fee might also include the cost of special packaging, such as coolboxes, cool packs and data loggers, as well as transport insurance to guarantee that you receive your medicine in good order.
When you buy Qulipta (atogepant), you can make the payment by bank transfer or by credit card. Payments are fully encrypted and secure. When paying by credit card, you can pay online once you have received your order confirmation. Please be aware that a 2.8% fee applies when paying by credit card.
Qulipta (atogepant) reimbursement
It might be possible for you to claim the cost of Qulipta (atogepant) via your country's healthcare system. Some countries have a government fund providing financial assistance for citizens to access lifesaving medical treatment abroad. The best thing would be to check with your country's own health ministry. We also highly recommend checking out local patient blogs, communities and patient organisations to find out more about your options.
Medical insurance
Generally, we do not support medical insurance, but we do provide you with an invoice after you make the payment that you may send to your medical insurance company so they can reimburse you. In some limited circumstances, we do accept insurance. Contact us for more details. You can pay by bank transfer or credit card.
Crowdfunding
Crowdfunding might also be an option for you. It is a means of raising funds by using an online platform to group together many small donations from friends, family and others, in order to help you afford medical treatment. Here are some crowdfunding platforms where you can seek support: GoFundMe, GiveForward, FundRazr and Watsi.
Shipping
Room temperature shipping
For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order.
Our standard delivery time varies from 5 to 10 working days.
The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.
You can also pick up your medicine from our partner pharmacy in Amsterdam or our partner pharmacy in Luxembourg after the order has been paid for.
Our Process
Four steps to access the medicines you need
How and where to access and buy Qulipta: You can access Qulipta from everyone.org if the drug has not been approved or is not available in your country.
- Step 1: You send a request for your medicine online
- Step 2: We verify your prescription and medical details
- Step 3: We source your medicine
- Step 4: We deliver your medicine
Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.
Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.
Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine. We will work hard to keep you informed at every step along the way and get your medicine to you quickly and safely. To date we have successfully delivered packages to over 75 countries around the world.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
